



BSW Formulary Updates and Recent Decisions – March 2026

New additions to BSWformulary and Change in Traffic Light Status (TLS)

- **Procainamide** – added with **RED** traffic light. Unlicensed use in resus department in trusts as per resus council guidelines.
- **Arize Formula** - added with **AMBER** traffic light as another option in CMPA in under 1 years.
- **Vevizye (ciclosporin) eye drops** – added with **AMBER** traffic light as another option in the treatment of dry eyes in a multi-dose bottle.
- **Efudix 5% 5-FU** – added with **RED** traffic light off-label use as a stat dose adjuvant therapy for odontogenic keratocysts in adults.
- **Eplerenone** – added with **AMBER** traffic light as a option in the treatment of primary aldosteronism in certain cohorts of patients.
- **CGM change in traffic light** – CGM changed from AMBER to **GREEN** traffic light in line with other local ICB's.
- **Sativex** – approved for adding to formulary with **AMBER** traffic light, pending financial approval.

New and Updated Prescribing Guidelines and Shared Care Agreements

- **DMARD SCA** – updated to reflect the update in the BSR guideline.
- **CMPA Guidance** – updated to include more information on plant-based options.
- **ONS Formulary** – format updated to improve clarity and other updates made to options based on cost effective prescribing.
- **Wound Care Formulary** – reviewed and updated to combine the three individual formularies to create a BSW wide version.
- **Jorveza Guidance** – includes information for prescribers in primary care taking on maintenance prescribing.
- **PPI Guidance** – updated to reflect additions to formulary and updated read codes.
- **Propranolol Risks Poster** – poster aimed to raise awareness of the risks when prescribing propranolol. Further amendments required before publication.

Minor amendments to Netformulary

- Licensing information was added to CGM formulary entries
- Insulin guidance was updated to include newer products
- Paeds vaccine section updated and linked from the adult section
- Enoxaparin and dalteparin entries and guidance updated
- Licensed spironolactone liquid added to entry, not for use in neonates
- Folic acid entry updated to include new dosing for pregnant women

What the BSW ICB formulary team are currently working on

- Paediatric constipation pathway
- Oral gepant prescribing guidance for chronic migraine prophylaxis
- Antibiotic guidance meningitis update
- GLP1 switch protocol for primary care
- LMWHs in pregnancy review



Bath and North East Somerset,
Swindon and Wiltshire Together

The BSW joint formulary remains under construction and is designed to be an evolving, dynamic resource. We are working to ensure the messages on GP prescribing systems and Optimise Profiles are in line with the joint formulary. If you discover information you believe to be inaccurate or misleading, or for further information, email bswicb.formulary@nhs.net